Ascendis Pharma A/S (ASND) earnings: date, estimates, results and stock reactions
Next earnings: Q1 FY2027 on 2027-02-10 (expected, before the open). EPS estimate 1.45, revenue estimate 504.1M.
Over the last 12 reports the stock moved 4.9% on average (either way), rising 7 times and falling 5. EPS beat estimates 7 of 12 times; revenue 7 of 12. Close before the report date to the first close after it (two trading sessions, covering before-the-open and after-the-close reports).
| Quarter | Reported | EPS | EPS estimate | EPS surprise | Revenue | Revenue estimate | Stock move |
|---|---|---|---|---|---|---|---|
| Q4 FY2026 | 2026-11-12 | 1.24 | 0.90 | +37.6% | 418.8M | 409.4M | +6.2% |
| Q3 FY2026 | 2026-08-13 | 3.29 | 1.71 | +92.4% | 387.5M | 376.8M | -2.7% |
| Q2 FY2026 | 2026-05-07 | 0.32 | 0.19 | +70.6% | 284.9M | 308.9M | +1.2% |
| Q1 FY2026 | 2026-02-11 | -0.64 | -0.06 | -966.7% | 344.8M | 292.3M | -2.7% |
| Q4 FY2025 | 2025-11-12 | -1.17 | -0.41 | -185.4% | 250.2M | 302.6M | +2.6% |
| Q3 FY2025 | 2025-08-07 | -0.93 | -1.42 | +34.5% | 186.1M | 233.1M | +4.9% |
| Q2 FY2025 | 2025-05-01 | -1.66 | -1.56 | -6.4% | 110.7M | 153.5M | +1.0% |
| Q1 FY2025 | 2025-02-12 | -0.68 | -1.20 | +43.3% | 180.1M | 125.4M | +19.2% |